Belépés

NCT04843345Felfüggesztve

Sjogren's Lung Study

A Prospective Cohort Study of Treatment Response in Sjogren's Syndrome-Related Lung Diseases Compared to Primary Idiopathic Lung Diseases

Forrás: ClinicalTrials.gov · Utoljára frissítve: 2022. okt. 27.

Rövid összefoglaló (regiszter, angolul)

Lung involvement in Sjögren's syndrome is common and causes reduced quality of life and increased mortality. Sjögren's syndrome-related lung diseases (SS-RLD) are classified and treated as the primary lung diseases they resemble. Whether this approach is optimal has not been evaluated thoroughly. A critical gap in knowledge is knowing whether SS-RLDs have a unique clinical course and response to therapy. Given the underlying immune system dysfunction in Sjögren's syndrome, the investigators hypothesize that patients with SS-RLD will be more likely to respond to immunosuppressive therapy than patients with the matching primary lung disease. To address this hypothesis, the investigators will prospectively screen for Sjogren's syndrome in patients presenting to pulmonary clinics and compare the clinical course and response to therapy in Sjogren's syndrome positive and negative patients.

Állapot (regiszter)
Felfüggesztve
Vizsgálattípus
Megfigyeléses
Résztvevők száma
500 (tervezett)
Első benyújtás
2021. ápr. 8.
Kezdés
2021. ápr. 1.
Elsődleges befejezés
2028. ápr. 1.
Fő szponzor
Stanford University
NCT-szám
NCT04843345

Ki nem vehet részt

Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.

Más betegség

  • Patients with interstitial lung disease due to a known or suspected trigger such as drug-induced (including but not limited to nitrofurantoin, amiodarone, methotrexate and other chemotherapies), inorganic dust exposure (including but not limited to asbestos, silica, hard metals, coal dust) or organic exposure (including but not limited to birds, hay, mold).

Egyéb

  • Patients who have taken a muscarinic antagonist or agonists within 7 days of planned testing
  • Patients who are unable to consent for themselves

Kiket keres a vizsgálat

  • Group 1: Interstitial Lung Disease and Other Parenchymal Lung Diseases
  • Known or suspected interstitial lung disease regardless of radiographic pattern
  • Interstitial lung disease due to alternative autoimmune etiology
  • Sarcoidosis
  • Organizing pneumonia
  • Hypersensitivity pneumonitis absent known or suspected trigger
  • Primary pulmonary lymphoma
  • Other idiopathic pulmonary conditions at discretion of study team
    • Group 2: Refractory Airway Symptoms
  • Chronic cough despite treatment trials with albuterol, proton-pump inhibitors and anti-histamine and intranasal corticosteroids
  • Persistent bronchial hyperreactivity (defined as positive response to methacholine challenge on spirometry or subjective worsening after exposure to airway irritants such as tobacco, pollution, etc) or persistent asthma symptoms despite trial of inhaled corticosteroid and long acting bronchodilator
  • Unexplained persistent bronchial wall thickening on CT imaging
  • Recurrent or chronic bronchiolitis (including but not limited to chronic bronchiolitis, obliterative bronchiolitis, lymphocytic bronchiolitis, constrictive bronchiolitis associated with bronchiolar destruction, and panbronchiolitis)
  • Bronchiectasis
  • Lymphocytic alveolitis on bronchoalveolar lavage absent hypersensitivity pneumonitis with known trigger or HIV
  • Recurrent bacterial pneumonia (greater than 2 episodes in 1 year, confirmed by focal consolidative opacity on chest imaging and requiring antibiotic therapy)
    • Group 3: Other
    • •Select patients outside the protocol testing schema who have one of the above lung diseases and are found to have Sjogren's syndrome through the course of their normal clinical care will be invited to participate in the data collection portion of the study for analyzing longitudinal outcomes.

Életkor a regiszterben: 18 év – - · Nem: nők és férfiak · Egészséges önkénteseket nem fogad

A teljes feltétellista: ClinicalTrials.gov

Helyszínek (1)

Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.

HelyszínVárosOrszágHelyszín állapota
Stanford University
Ennek a helyszínnek vagy a koordinátora? Erősítsd meg az állapotát
StanfordEgyesült ÁllamokIsmeretlen állapot

Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.